Here are three things to know.
- The Auvi-Q 0.1 milligram auto-injector is intended to treat infants and young children who weigh 16.5 to 33 pounds and are at risk for serious allergic reactions.
- The device contains a shorter needle and lower epinephrine dose than other Auvi-Q auto-injectors already on the market.
- Kaléo expects Auvi-Q 0.1 milligram to be available for patients by mid-2018.
More articles on supply chain:
4 ways the FDA is addressing the saline bag shortage
FDA approves first pill with digital ingestion tracking system
Mylan lays off up to 300 employees
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
